1Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease[J]. Int Urol Nephrol, 2007, 39: 1209-1216.
2Prie D, Urena Torres P, Friedlander G. Latest findings in phosphate homeostasis[J]. Kidney Int, 2009, 75: 882- 889.
3iathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD EJ]. J Am Soc Nephrol, 2008,19: 1092-1105.
4Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients[J]. Nephrol Dial Transplant, 2007, 22: 2909-2916.
5Kidney Disease: Improving Global Outcomes (KDIGO) CKD- MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD- MBD) [J]. Kidney Int, 2009, 76(suppl 113):S1-130.
6Frazo JM, Adrago T. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects[J]. Nephron Clin Pract, 2012,120(2):c108-119.
7Navaneethan SD, Palmer SC, Craig JC, harms of phosphate binders in CKD: of randomized controlled trials[J] 2009. 54: 619-637. et al. Benefits and a systematic review Am J Kidney Dis.
8Mehrotra R, Martin K3, Fishbane S, et al. Higher stre- ngth lanthanum carbonate provides serum phosphorus con- trol with a low tablet burden and is preferred by patients and physicians: a multicenter study[J]. Clin 3 hmSoc Nephrol, 2008, 3: 1437-1445.
9McIntyre CW, Pal P, Warwick G, et al. Iron-magnesium hydroxycarbonate (Fermagate): a novel noncalcium-con- taining phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients[J]. Clin J Am Soc Nephrol, 2009, 4: 401-409.
